The Cancer Immune Responsiveness Task Force hosted a two-day workshop on May 14-15 that brought together stakeholders to discuss topics including:
This workshop was held back-to-back with a two-day workshop from the Biomarkers Task Force in May 2018.
As a benefit for attending the 2018 Cancer Immune Responsiveness Workshop, the Society for Immunotherapy of Cancer (SITC) provides enduring materials free of charge for the specific programs for which attendees were registered. Attendees of the 2018 Cancer Immune Responsiveness Workshop can click here to access enduring materials.
If you are a SITC member, or member of the general public, but did not register to attend the 2018 Cancer Immune Responsiveness Workshop, the materials are available for purchase at the link below.
2018 Cancer Immune Responsiveness Workshop enduring materials will become available free of charge for the following individuals on the following dates:
Presentations and video recordings are available based on permission from presenters.
Josue Samayoa, PhDAbbVie
Stefanie Spranger, PhDKoch Institute for Integrative Cancer Research at MIT
Join SITC members, Drs. Vincenzo Bronte, Lorenzo Galluzzi and Jérôme Galon, for the Primer on Cancer Immunology and Immunotherapy at the International Conference on Immunotherapy Radiotherapy Combinations Sept. 20–22 in Paris. Attention SITC members! ...
This two day program is divided into a lectures series presented by world class scientists in the field of immuno-oncology, and a hands-on workshop laboratory to explore the optimization and troubleshooting of Opal staining, multispectral image acquisition ...
Currently scfvs, antibody-derived single chain variable fragment based CAR to target CD19 antigen is the most common CAR strategy clinically used. But based on the cited article, tumor cells can be targeted also through use of non-antibody based approahes.This ...
Dear Dr. Ramakrishna, Below please find a short summary of immunotherapies targeting CD123, CD33. All can be found on clinicaltrials.gov. I have heard that the City of Hope (COH) CAR T cells anti-CD123 study is showing early promise, but I have no ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com